ISRCTN ISRCTN25106564
DOI https://doi.org/10.1186/ISRCTN25106564
Secondary identifying numbers EAME2011CoughAssist023
Submission date
12/11/2013
Registration date
26/11/2013
Last edited
15/01/2018
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
We are carrying out a study on critically ill intubated (a tube inserted via the nose or mouth to keep the airways open) and ventilated (allowing air into the lungs) patients. The first studies to demonstrate mechanical in-exsufflation (IEM) as an effective technique for draining fluid/mucus were conducted in the 1950s. This technique basically mimics a cough in those patients unable to produce a cough to clear the fluid/mucus. This technique in combination with ventilation has been used widely in neuromuscular disease. There is not a lot of data on the use of IEM devices in the intensive care unit (ICU) setting. Currently the technique to remove fluid/mucus is called endotracheal aspiration; serious complications can sometimes occur. This study aims to find out if the use of an IEM device (CoughAssist E70) with conventional tracheal suctioning will improve the drainage of fluid/mucus in intubated and ventilated patients.

Who can participate?
Adult men and women admitted to the intensive care unit who are critically ill and require intubation and ventilation.

What does the study involve?
Subjects will receive both treatments (in-exsufflation with a device [CoughAssist E70] and conventional tracheal suctioning) in a random order. Subjects will be followed up daily until Day 14 and then until discharge from hospital. Subjects will be contacted by telephone on Day 90.

What are the possible benefits and risks of participating?
We believe that the CoughAssist E70 IEM device when used with conventional suctioning will improve the drainage of fluid/mucus. There is data available to demonstrate the effective use of this technology in critically ill patients, but there is a lack of evidence in the ICU setting. The CoughAssist E70 IEM equipment will be fully tested to ensure safety. Subjects will be closely monitored by trained clinical staff.

Where is the study run from?
Service de Pneumologie et de Réanimation, GH Pitié Salpêtrière – Charles Foix, Paris, France

When is the study starting and how long is it expected to run for?
January 2014 to December 2016

Who is funding the study?
Philips Respironics (France)

Who is the main contact?
Prof. Alexandre Demoule
alexandre.demoule@psl.aphp.fr

Contact information

Prof Alexandre Demoule
Scientific

Service de Pneumologie et de
Réanimation
GH Pitié Salpêtrière – Charles Foix
47 et 83 Bd de l’hôpital
75651 Paris cedex 13
Paris
75651
France

ORCiD logoORCID ID 0000-0002-0432-7217
Email alexandre.demoule@psl.aphp.fr

Study information

Study designSingle centre prospective randomized cross-over study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleIn-exsufflation mechanics in intubated patients: a randomized trial
Study acronymCOUGH ICU
Study objectivesThe use of an in-exsufflation (IEM) device (CoughAssist E70) with conventional tracheal suctioning will improve the drainage of tracheal secretions in intubated and ventilated patients.
Ethics approval(s)Committee to Protect People (Comité de Protection des Personnes Île de France VI)
Health condition(s) or problem(s) studiedAcute Respiratory Failure requiring mechanical ventilation and endotracheal tube intubation
InterventionInclusion:
1. Demographics
2. Duration of mechanical ventilation before inclusion
3. Pathology requiring intubation, history
4. Severity Score SAPS II and SOFA
5. Clinic: blood pressure, heart and respiratory rates, score consciousness (Glasgow) or sedation (RASS), diagnosis (clinical and radiological)
6. Ventilator settings (mode, pressure, volume, Fraction of Inspired Oxygen [FiO2])
7. Diameter of the endotracheal tube
8. Arterial blood gas

Subjects will then receive both treatments (in-exsufflation [IEM] device [CoughAssist E70] or conventional tracheal suctioning) in a random order.

Daily until extubation or Day 14:
1. Number of aspirations
2. Occurrence of a complication with the waning of a drainage procedure tracheobronchial secretions
3. Volume of sputum collected
4. Score of gravity SOFA
5. Blood gases
6. Settings fan (mode, pressure , volume, FiO2)
7. Occurrence of VAP and atelectasis, pneumothorax, adverse event
8. Score of consciousness and sedation (RASS)
9. Tolerance technique EVA if the patient can respond
10. Lung density measured by impedance

Day 28:
1. Duration of invasive mechanical ventilation
2. Duration of hospitalization in intensive care unit (ICU)

Day 90:
1. Mortality in the ICU
2. Hospital mortality
3. Mortality at the end of the stay

Follow up:
1. Monitoring will be carried out until ICU discharge and hospital discharge to determine the ICU and hospital stay mortality
2. Patients will be contacted by telephone at Day 90 to determine mortality. This review will be conducted by one of the investigators.
Intervention typeOther
Primary outcome measureThe number of drainage procedures for tracheobronchial secretions necessary for 24h
Secondary outcome measures1. The volume of bronchial secretions collected daily
2. The incidence of ventilator-acquired pneumonia defined by the presence of two of the following three criteria:
2.1. Hyperthermia > 38.3 ° C controlled to 4 hours apart
2.2. Leukocytosis > 10 G / l
2.3. Sputum purulent
And the following two criteria:
2.4. Microbiological documentation as defined in the study protocol
2.5. New X-ray image evaluated by the two-point increase Score Weinberg 26
3. The incidence of atelectasis (radiographic or endoscopic diagnosis)
4. The clinical safety of the technique assessed by a visual analogue rating scale in conscious patients
5. The failure of the test airway defined by the occurrence of:
5.1. Increased heart rate of more than 30/min
5.2. Increased respiratory rate of more than 10/min
5.3. Respiratory distress with clinical signs of struggle
5.4. Change in systolic blood pressure over 30 mmHg
5.5. Desaturation of more than 4% SpO2
5.6. Increased the capnia more than 5 mmHg
6. The failure of extubation is defined by the need for reintubation within 72 hours. Reintubation criteria as defined in the study protocol
6.1. Criterion immediate intubation:
6.1.1. Cardiac or respiratory arrest
6.1.2. Respiratory break with loss of consciousness or dying breath
6.1.3. Psychomotor agitation not controlled by sedation
6.1.4. Dimensions persistent
6.1.5. Inhalation massive
6.1.6. Heart rate < 50/min with somnolence
6.1.7. Severe hemodynamic dysfunction not responding to circulatory expansion and administration of vasoactive drugs.
6.2. Criterion mechanical ventilation in non-invasive ventilation and invasive ventilation in case of persistent non-invasive ventilation after:
6.2.1. Respiratory acidosis with arterial pH > 7.35 or PaCO2 > 45 mmHg
6.2.2. SpO2 < 90% or PaO2 < 60 mmHg with FiO2 Inspirational > 50%
6.3.3. Respiratory rate > 35/min
6.3.4. Disorder consciousness, agitation or asterixis
6.3.5. Clinical signs of respiratory control or exhaustion: use accessory respiratory muscles or swinging thoracoabdominal
7. The duration of invasive mechanical ventilation
8. The length of stay in the ICU
9. The length of hospital stay
10. Mortality in the ICU
11. In-hospital mortality
Overall study start date01/01/2014
Completion date31/12/2016

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants40-67
Key inclusion criteria1. Patient ventilated on endotracheal tube for less than 7 days
2. Duration of mechanical ventilation predicted > 48h
Key exclusion criteria1. Pre-existing neuromuscular pathology, suspected or proven
2. State of shock uncontrolled defined by the administration of norepinephrine or adrenaline at a dose> 0.3 mcg/kg/min
3. Moderate to severe acute respiratory distress syndrome (ARDS) defined by a PaO2/FiO2 ratio <200 mmHg
4. Undrained pneumothorax
5. Hemoptysis active or less than 15 days
6. Intracranial hypertension
7. Decision to limit or stop the treatment
8. Pregnancy
9. Unable to follow study related procedures as explained by the investigator
10. Minor patient
Date of first enrolment01/01/2014
Date of final enrolment01/11/2016

Locations

Countries of recruitment

  • France

Study participating centre

Service de Pneumologie et de
Paris
75651
France

Sponsor information

Philips Respironics (France)
Industry

Bâtiment Verdi
33, rue de Verdun - BP 313
Suresnes
92150
France

Email sarah.hinch@philips.com
ROR logo "ROR" https://ror.org/05jz46060

Funders

Funder type

Industry

Philips Respironics (France)

No information available

Results and Publications

Intention to publish date31/01/2019
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination planPlanned publication in a high-impact peer reviewed journal approximately end of Jan 2019.
IPD sharing planThe current data sharing plans for the current study are unknown and will be made available at a later date.

Editorial Notes

15/01/18: Publication plan, intention to publish date and ORCID ID were added.
22/12/2017: Internal review.
05/10/2016: the following changes were made to the trial record:
1. The recruitment end date was changed from 01/09/2015 to 01/11/2016.
2. The overall trial end date was changed from 01/09/2015 to 31/12/2016.